ReForm Biologics Announces Collaboration Agreement with Astellas Pharma Inc.
Under the terms of the agreement, Astellas will provide funding for the collaboration and the work will be performed at ReForm Biologics’ facilities in Woburn, Massachusetts.
“We are excited to initiate this collaboration with Astellas, a global leader in turning innovative science into value for patients. We appreciate the efforts of Astellas Innovation Management team in getting the agreement completed,” said John M. Sorvillo, Ph.D., Chief Executive Officer, ReForm Biologics. “This collaboration will demonstrate how new formulation technologies can optimize dosing and support life cycle management in pharmaceutical drug development programs. We look forward to working with Astellas to support the development of this clinical-stage asset.”
About ReForm Biologics
ReForm Biologics has developed a technology platform that transforms the formulation of biotherapeutics for the ultimate benefit of patients. Our patented, FDA-friendly technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for our biopharmaceutical partners. With multiple industry alliances to date, we offer formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics.
We don’t make biologics — we make biologics better. www.reformbiologics.com
About Astellas Pharma Inc.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at http://www.astellas.com/en
Shoreline Biotech Communications
Source: ReForm Biologics